Durvalumab
Drug timelines are a Plus or Pro feature.
393 regulatory and trial events tracked for Durvalumab, covering 2015-10-27 to 2026-08-28. Get the full timeline:
Most recent: Clinical Trial Update: Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) [Phase 3]